Bone Destruction-Chemotactic Osteoprogenitor Cells Deliver Liposome Nanomedicines for the Treatment of Osteosarcoma and Osteoporosis Journal: ACS Nano Published: 2024-10-18 DOI: 10.1021/acsnano ...

There are approximately 50 chemokines and 20 chemokine receptors in humans. To improve CAR T-cell homing to osteosarcoma, the researchers had to first determine which chemokines are expressed by ...

A groundbreaking review by researchers at Central South University highlights six critical signaling pathways—CCNE1/CDK2, MYC/CDK9, CDK4/CDK6/FOXM1, PTEN/PI3K/AKT/mTOR, AURKB, and VEGFA/VEGFR—as ...

Osteosarcoma is a type of bone cancer that predominantly affects adolescents. Reliable models that can predict prognosis and treatment response can help improve patient outcomes. However ...

The most recent PRV sale occurred in June 2025, valued at $160 million. The osteosarcoma treatment market was estimated at $1.2 billion in 2022 according to Data Bridge Market Research.

1-year Event Free Survival (EFS) of 32.5% vs. 20% 1-year EFS for comparator Interim 1-year and 18-month Overall Survival (OS) of 90.4% 0 Grade 3, 4 or 5 Treatment-related Adverse Events (AEs) 41 ...

Redirecting B7-H3.CAR T cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models. Clinical Cancer Research, 2024; DOI: 10.1158/1078-0432.CCR-23-3298 ...